Naples, United States
Attralus, founded in 2019, is a clinical stage biopharmaceutical company headquartered in the United States. The company is focused on the development of innovative therapies for patients suffering from systemic amyloidosis, a complex disease with few treatment options. Attralus' proprietary technology, pan-amyloid removal (PAR) therapeutics, aims to bind and eliminate toxic amyloid deposits from organs and tissues, addressing the underlying issue in all systemic amyloidosis diseases.
Attralus' promising approach has attracted significant interest from notable investors. In its most recent funding round, the company secured a $56.00 million Series B investment on 06 February 2024. This round included participation from prominent funds and partners such as Vivo Capital, Logos Capital, Sarissa Capital, VenBio Partners, Surveyor Capital, Bristol-Myers Squibb, and Alpha Wave Ventures.
With its transformative potential and robust financial backing, Attralus is well-positioned to advance its therapeutic solutions, targeting a broad spectrum of patients affected by systemic amyloidosis.
